Table 1 .

Interaction MVA of each signature in the clinical validation cohort

	Chemo-GS1		RT-GS2		ChemoRT-GS3
	P-value	HR	P-value	HR	P-value	HR
Chemo-GS:Chemo	0.8934	0.98 [0.72–1.33]	Not included		Not included
Chemo-GS	0.0284	0.76 [0.6–0.97]
RT-GS:RT	Not included		0.0009	0.4 [0.23–0.69]	Not included
RT-GS			0.0019	2.26 [1.35–3.77]
ChemoRT-GS:ChemoRT	Not included		Not included		0.0204	0.56 [0.34–0.91]
ChemoRT-GS					0.5467	1.13 [0.76–1.68]
Chemo	0.2085	0.68 [0.37–1.24]	0.0608	0.56 [0.3–1.03]	0.1876	0.67 [0.36–1.22]
RT	<0.0001	0.41 [0.29–0.57]	<0.0001	0.36 [0.26–0.51]	<0.0001	0.43 [0.3–0.6]
ChemoRT	0.8923	0.96 [0.49–1.85]	0.7482	1.12 [0.57–2.18]	0.8708	0.95 [0.49–1.84]
Prior treatment	0.1815	0.71 [0.42–1.18]	0.3877	0.8 [0.48–1.33]	0.2474	0.74 [0.45–1.23]
Resection	0.2021	1.21 [0.9–1.63]	0.3255	1.16 [0.87–1.55]	0.2664	1.18 [0.88–1.58]
Male vs Female	0.2974	1.12 [0.91–1.37]	0.2673	1.12 [0.91–1.38]	0.2486	1.13 [0.92–1.4]
Age	<0.0001	1.03 [1.02–1.04]	<0.0001	1.03 [1.02–1.04]	<0.0001	1.03 [1.02–1.04]

¹Left: interaction MVA for Chemo-GS (as a continuous variable) with alkylating chemotherapy.

²Middle: interaction MVA for RT-GS (as a continuous variable) with RT.

³Right: interaction MVA for ChemoRT-GS (as a continuous variable) with alkylating chemotherapy and RT.